Loading clinical trials...
Loading clinical trials...
A Phase 1, 2-Part, Multicenter, Open-Label, 3-Arm Study to Determine the Effect of Enasidenib (CC-90007) on the Pharmacokinetics of Single Oral Doses of Caffeine, Dextromethorphan, Fexofenadine, Flurbiprofen, Midazolam, Omeprazole, Pioglitazone, and Rosuvastatin in Patients With Acute Myeloid Leukemia
Conditions
Interventions
enasidenib
Arm 1 probes
+2 more
Locations
10
Australia
Local Institution - 103
Concord, New South Wales, Australia
Local Institution - 107
Adelaide, South Australia, Australia
Local Institution - 106
Clayton, Victoria, Australia
Local Institution - 102
Heidelberg, Victoria, Australia
Local Institution - 105
Nedlands, Western Australia, Australia
Local Institution - 101
Melbourne, Australia
Start Date
October 4, 2018
Primary Completion Date
September 22, 2023
Completion Date
December 22, 2023
Last Updated
February 28, 2024
NCT06852222
NCT06580106
NCT06501196
NCT06384261
NCT06382168
NCT06326268
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions